As demonstrated above, UDCA treatment could reduce the serum ALT and AST levels, and improve hepatic inflammation in a dose-dependent pattern; thus, we further evaluated the effect of UDCA on the intestinal barrier function and levels of serum endotoxemia and inflammatory cytokines in NASH mice. This evidence concerns the gene GPT and serum lipopolysaccharide activity.